Fatality and risk features for prognosis in COVID-19 according to the care approach - a retrospective cohort study

PLoS One. 2021 Mar 23;16(3):e0248869. doi: 10.1371/journal.pone.0248869. eCollection 2021.

Abstract

Introduction: This study analyzed the impact of a categorized approach, based on patients' prognosis, on major outcomes and explanators in patients hospitalized for COVID-19 pneumonia in an academic center in Spain.

Methods: Retrospective cohort study (March 3 to May 2, 2020). Patients were categorized according to the followed clinical management, as maximum care or limited therapeutic effort (LTE). Main outcomes were all-cause mortality and need for invasive mechanical ventilation (IMV). Baseline factors associated with outcomes were analyzed by multiple logistic regression, estimating odds ratios (OR; 95%CI).

Results: Thirty-hundred and six patients were hospitalized, median age 65.0 years, 57.8% males, 53.3% Charlson index ≥3. The overall all-cause fatality rate was 15.0% (n = 46). Maximum care was provided in 238 (77.8%), IMV was used in 38 patients (16.0%), and 5.5% died. LTE was decided in 68 patients (22.2%), none received IMV and fatality was 48.5%. Independent risk factors of mortality under maximum care were lymphocytes <790/mm3, troponin T >15ng/L and hypotension. Advanced age, lymphocytes <790/mm3 and BNP >240pg/mL independently associated with IMV requirement.

Conclusion: Overall fatality in the cohort was 15% but markedly varied regarding the decided approach (maximum care versus LTE), translating into nine-fold higher mortality and different risk factors.

MeSH terms

  • Age Factors
  • Aged
  • COVID-19 / mortality
  • COVID-19 / pathology*
  • COVID-19 / virology
  • Cohort Studies
  • Comorbidity
  • Female
  • Hospital Mortality
  • Humans
  • Logistic Models
  • Male
  • Middle Aged
  • Odds Ratio
  • Prognosis
  • RNA, Viral / metabolism
  • Respiration, Artificial
  • Retrospective Studies
  • Risk Factors
  • SARS-CoV-2 / genetics
  • SARS-CoV-2 / isolation & purification
  • Survival Rate

Substances

  • RNA, Viral

Grants and funding

The author(s) received no specific funding for this work.